Cantargia
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Cantargia is a Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and inflammatory/autoimmune diseases. Our development programme includes the candidate drugs nadunolimab (CAN04), currently in phase IIa clinical studies, and CAN10, currently in preclinical phase, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Mid Cap). Cantargia AB was founded in 2009-2010 with the aim of refining a discovery by Professor Thoas Fioretos and Doctor Marcus Järås of Lund University. Their research showed that leukemic stem cells express a protein on their surface – IL1RAP – that is not expressed to as great a degree on normal stem cells. Further research demonstrated that this protein is also found on cancer cells from a large number of solid tumor types.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-17 21:30 |
Earnings Release
Cantargia announces preliminary topline efficacy results from the phase 2 TRIFO…
|
English | 117.3 KB | |
| 2025-07-17 21:30 |
Earnings Release
Cantargia meddelar preliminära topline-effektresultat från fas 2-studien TRIFOU…
|
Swedish | 118.2 KB | |
| 2025-07-15 08:45 |
Regulatory News Service
Cantargia tillkännager försäljningen av IL1RAP immunologiprogrammet CAN10 till …
|
Swedish | 111.6 KB | |
| 2025-07-15 08:45 |
Regulatory News Service
Cantargia announces the acquisition of its CAN10 IL1RAP immunology program by O…
|
English | 111.5 KB | |
| 2025-07-08 10:17 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 9.5 KB | |
| 2025-06-17 19:45 |
Capital/Financing Update
Cantargia tecknar avtal om lånefacilitet om 50 miljoner kronor, som förlänger b…
|
Swedish | 107.1 KB | |
| 2025-06-17 19:45 |
Capital/Financing Update
Cantargia signs SEK 50 million financing facility agreement, extending cash run…
|
English | 107.4 KB | |
| 2025-05-15 16:30 |
AGM Report
Bulletin from the Annual General Meeting in Cantargia AB
|
English | 93.9 KB | |
| 2025-05-15 16:30 |
Declaration of Voting Results & Voting Rights Announcements
Kommuniké från årsstämma i Cantargia AB
|
Swedish | 94.8 KB | |
| 2025-05-13 07:00 |
Quarterly Report
|
Swedish | 3.4 MB | |
| 2025-05-13 07:00 |
Interim Report
|
English | 3.4 MB | |
| 2025-03-21 10:36 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 9.1 KB | |
| 2025-03-12 07:00 |
Regulatory News Service
Första patienten rekryterad i Cantargias leukemistudie med nadunolimab
|
Swedish | 111.0 KB | |
| 2025-03-12 07:00 |
Regulatory News Service
First patient enrolled in Cantargia’s leukemia study with nadunolimab
|
English | 111.8 KB | |
| 2025-03-05 10:30 |
Earnings Release
Cantargia reports promising CAN10 phase 1 data from first multiple dose cohort,…
|
English | 109.7 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
BSF ENTERPRISE PLC | United Kingdom | BSFA | |
|
Can-Fite BioPharma Ltd. | Israel | CANF | |
|
Captor Therapeutics S.A. | Poland | CTX | |
|
Carbiotix AB | Sweden | CRBX | |
|
Cellectis | France | ALCLS | |
|
CELLULAR GOODS PLC | United Kingdom | CBX | |
|
Celyad Oncology SA | Belgium | CYAD | |
|
Cereno Scientific AB | Sweden | CRNO | |
|
Cessatech A/S | Denmark | CESSA | |
|
CHOSA Oncology AB | Sweden | CHOSA |